

Frederick L Ruberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5470279/publications.pdf>

Version: 2024-02-01

101
papers

9,470
citations

76196

40
h-index

39575

94
g-index

104
all docs

104
docs citations

104
times ranked

7783
citing authors

#	ARTICLE	IF	CITATIONS
1	Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. <i>Circulation</i> , 2016, 133, 2404-2412.	1.6	1,335
2	Pericardial Fat, Visceral Abdominal Fat, Cardiovascular Disease Risk Factors, and Vascular Calcification in a Community-Based Sample. <i>Circulation</i> , 2008, 117, 605-613.	1.6	896
3	Transthyretin Amyloid Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2872-2891.	1.2	573
4	Testing of Low-Risk Patients Presenting to the Emergency Department With Chest Pain. <i>Circulation</i> , 2010, 122, 1756-1776.	1.6	545
5	Transthyretin (TTR) Cardiac Amyloidosis. <i>Circulation</i> , 2012, 126, 1286-1300.	1.6	510
6	Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 331.	3.8	434
7	Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2020, 142, e7-e22.	1.6	338
8	Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. <i>Circulation: Heart Failure</i> , 2019, 12, e006075.	1.6	312
9	Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging. <i>JAMA Cardiology</i> , 2016, 1, 880.	3.0	304
10	Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. <i>Blood</i> , 2011, 118, 4346-4352.	0.6	259
11	Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin. <i>Circulation</i> , 2016, 133, 282-290.	1.6	230
12	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMLI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2—evidence base and standardized methods of imaging. <i>Journal of Nuclear Cardiology</i> , 2019, 26, 2065-2123.	1.4	230
13	Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment. <i>Trends in Cardiovascular Medicine</i> , 2018, 28, 10-21.	2.3	211
14	Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: The Transthyretin Amyloidosis Cardiac Study (TRACS). <i>American Heart Journal</i> , 2012, 164, 222-228.e1.	1.2	209
15	Persistent left superior vena cava: a case report and review of literature. <i>Cardiovascular Ultrasound</i> , 2008, 6, 50.	0.5	198
16	Native T1 and Extracellular Volume in Transthyretin Amyloidosis. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 810-819.	2.3	172
17	Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis. <i>Journal of Nuclear Cardiology</i> , 2014, 21, 925-939.	1.4	155
18	Diagnostic and Prognostic Utility of Cardiovascular Magnetic Resonance Imaging in Light-Chain Cardiac Amyloidosis. <i>American Journal of Cardiology</i> , 2009, 103, 544-549.	0.7	145

#	ARTICLE	IF	CITATIONS
19	Cardiac Scintigraphy With Technetium-99m-Labeled Bone-Seeking Tracers for Suspected Amyloidosis. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2851-2862.	1.2	131
20	Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis. <i>Blood</i> , 2019, 133, 215-223.	0.6	118
21	Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans. <i>Genetics in Medicine</i> , 2017, 19, 733-742.	1.1	116
22	Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR). <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 62-67.	1.4	108
23	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2 "Evidence Base and Standardized Methods of Imaging." <i>Journal of Cardiac Failure</i> , 2019, 25, e1-e39.	0.7	107
24	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2 "Diagnostic criteria and appropriate utilization." <i>Journal of Nuclear Cardiology</i> , 2020, 27, 659-673.	1.4	97
25	Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience. <i>ESC Heart Failure</i> , 2018, 5, 772-779.	1.4	89
26	Pressure-Volume Relationships in Patients With Transthyretin (ATTR) Cardiac Amyloidosis Secondary to V122I Mutations and Wild-Type Transthyretin. <i>Circulation: Heart Failure</i> , 2011, 4, 121-128.	1.6	84
27	The response of FDG uptake to immunosuppressive treatment on FDG PET/CT imaging for cardiac sarcoidosis. <i>Journal of Nuclear Cardiology</i> , 2017, 24, 413-424.	1.4	71
28	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2 "Diagnostic Criteria and Appropriate Utilization." <i>Journal of Cardiac Failure</i> , 2019, 25, 854-865.	0.7	70
29	Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 1057-1064.	0.5	60
30	Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. <i>BMC Family Practice</i> , 2020, 21, 198.	2.9	60
31	In vivo Detection of Vulnerable Atherosclerotic Plaque by MRI in a Rabbit Model. <i>Circulation: Cardiovascular Imaging</i> , 2010, 3, 323-332.	1.3	57
32	Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis. <i>Journal of Cardiac Failure</i> , 2020, 26, 753-759.	0.7	57
33	Can 99mTc-Pyrophosphate Aid in Early Detection of Cardiac Involvement in Asymptomatic Variant TTR Amyloidosis?. <i>JACC: Cardiovascular Imaging</i> , 2017, 10, 713-714.	2.3	55
34	Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin. <i>Circulation: Heart Failure</i> , 2018, 11, e004000.	1.6	55
35	Early Detection of Multiorgan Light-Chain Amyloidosis by Whole-Body ¹⁸ F-Florbetapir PET/CT. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1234-1239.	2.8	54
36	Adverse Vascular Risk is Related to Cognitive Decline in Older Adults. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 1361-1373.	1.2	49

#	ARTICLE	IF	CITATIONS
37	Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model. <i>JAMA Cardiology</i> , 2017, 2, 305.	3.0	48
38	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€”Evidence Base and Standardized Methods of Imaging. <i>Circulation: Cardiovascular Imaging</i> , 2021, 14, e000029.	1.3	48
39	The Vanderbilt Memory & Aging Project: Study Design and Baseline Cohort Overview. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 539-559.	1.2	44
40	Myocardial infarction with â€œclean coronariesâ€•caused by amyloid light-chain AL amyloidosis: a case report and literature review. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2011, 18, 160-164.	1.4	42
41	Atherothrombosis: Plaque instability and thrombogenesis. <i>Progress in Cardiovascular Diseases</i> , 2002, 44, 381-394.	1.6	41
42	Improved Quantification of Cardiacâ€”Amyloid Burden in Systemicâ€”Light Chainâ€”Amyloidosis. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 1325-1336.	2.3	41
43	Identification of Atherosclerotic Lipid Deposits by Diffusion-Weighted Imaging. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 1440-1446.	1.1	40
44	High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center. <i>Blood</i> , 2012, 120, 4445-4446.	0.6	38
45	MRI of Atherothrombosis Associated With Plaque Rupture. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 240-245.	1.1	37
46	The Relationship of Ectopic Lipid Accumulation to Cardiac and Vascular Function in Obesity and Metabolic Syndrome. <i>Obesity</i> , 2010, 18, 1116-1121.	1.5	35
47	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2â€”evidence base and standardized methods of imaging. <i>Journal of Nuclear Cardiology</i> , 2021, 28, 1769-1774.	1.4	34
48	Light-Chain Amyloidosis With Echocardiographic Features of Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2008, 101, 674-676.	0.7	31
49	Identification of cholesteryl esters in human carotid atherosclerosis by ex vivo image-guided proton MRS. <i>Journal of Lipid Research</i> , 2006, 47, 310-317.	2.0	27
50	Myocardial Lipid Accumulation in the Diabetic Heart. <i>Circulation</i> , 2007, 116, 1110-1112.	1.6	26
51	The influence of pericardial fat upon left ventricular function in obese females: evidence of a site-specific effect. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2014, 16, 37.	1.6	26
52	Establishment of brain natriuretic peptide â€”based criteria for evaluating cardiac response to treatment in light chain (AL) amyloidosis. <i>British Journal of Haematology</i> , 2020, 188, 424-427.	1.2	25
53	Cardiac Amyloidosis: Multimodal Imaging of Disease Activity and Response to Treatment. <i>Circulation: Cardiovascular Imaging</i> , 2021, 14, e009025.	1.3	24
54	Stroke risk interacts with Alzheimer's disease biomarkers on brain aging outcomes. <i>Neurobiology of Aging</i> , 2015, 36, 2501-2508.	1.5	23

#	ARTICLE	IF	CITATIONS
55	Prothrombotic determinants of coronary atherothrombosis. <i>Vascular Medicine</i> , 2002, 7, 289-299.	0.8	21
56	Cardiac Amyloidosis: Evolving Approach to Diagnosis and Management. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2011, 13, 528-542.	0.4	20
57	T1 Mapping in Cardiac Amyloidosis. <i>JACC: Cardiovascular Imaging</i> , 2013, 6, 498-500.	2.3	17
58	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of “Diagnostic Criteria and Appropriate Utilization. <i>Circulation: Cardiovascular Imaging</i> , 2021, 14, e000030.	1.3	16
59	Retinol binding protein 4 (RBP4) concentration identifies V122I transthyretin cardiac amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 120-121.	1.4	14
60	A new era of amyloidosis: the trends at a major US referral centre. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 192-196.	1.4	14
61	Quantitative [18F]florbetapir PET/CT may identify lung involvement in patients with systemic AL amyloidosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1998-2009.	3.3	14
62	False Positive 99mTc-Pyrophosphate Scanning Leading to Inappropriate Tafamidis Prescriptions. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 2042-2044.	2.3	13
63	Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2022, 29, 71-78.	1.4	13
64	Challenging the myths of cardiac amyloidosis. <i>European Heart Journal</i> , 2017, 38, 1909-1912.	1.0	12
65	Predictors of hematologic response and survival with stem cell transplantation in <sc>AL</sc> amyloidosis: A 25-year longitudinal study. <i>American Journal of Hematology</i> , 2022, 97, 1189-1199.	2.0	12
66	An Intracardiac Accessory Thyroid Gland. <i>American Journal of Cardiology</i> , 2006, 97, 926-928.	0.7	11
67	ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 204.	1.2	11
68	Left Atrial Mechanics Associates With Paroxysmal Atrial Fibrillation in Light-Chain Amyloidosis Following Stem Cell Transplantation. <i>JACC: CardioOncology</i> , 2020, 2, 721-731.	1.7	11
69	Computed Tomography of the Coronary Arteries. <i>Circulation</i> , 2005, 112, .	1.6	10
70	Multiple arterial and venous thromboembolic complications in AL amyloidosis and cardiac involvement: a case report and literature review. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2012, 19, 156-160.	1.4	10
71	Once AL amyloidosis: not always AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 139-140.	1.4	10
72	Nuclear Tracers for Transthyretin Cardiac Amyloidosis. <i>Circulation: Cardiovascular Imaging</i> , 2013, 6, 162-164.	1.3	9

#	ARTICLE	IF	CITATIONS
73	Cardiovascular Magnetic Resonance Visualization of Cardiac Amyloid Infiltration. <i>Circulation</i> , 2015, 132, 1525-1527.	1.6	9
74	Prevalence of mutant ATTR cardiac amyloidosis in elderly African Americans with heart failure. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 253-255.	1.4	9
75	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of "Evidence Base and Standardized Methods of Imaging. <i>Journal of Cardiac Failure</i> , 2022, 28, e1-e4.	0.7	8
76	Cardiac Scintigraphy and Screening for Transthyretin Cardiac Amyloidosis. <i>Circulation</i> , 2021, 144, 1005-1007.	1.6	8
77	More Than Meets the Eye: Time for a New Imaging Paradigm to Test for Cardiac Amyloidosis. <i>Journal of Cardiac Failure</i> , 2018, 24, 87-89.	0.7	7
78	Early Diagnosis of Cardiac Amyloidosis by Carpal Tunnel Surgery. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2051-2053.	1.2	7
79	Cardiac Amyloidosis. <i>Circulation: Cardiovascular Imaging</i> , 2017, 10, e006186.	1.3	6
80	Impact of Genetic Testing in Transthyretin (ATTR) Cardiac Amyloidosis. <i>Current Heart Failure Reports</i> , 2019, 16, 180-188.	1.3	6
81	Myocardial Composition in Light-Chain Cardiac Amyloidosis More Than 1 Year After Successful Therapy. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 594-603.	2.3	6
82	Echocardiography and Survival in Light Chain Cardiac Amyloidosis. <i>Circulation: Cardiovascular Imaging</i> , 2018, 11, e007826.	1.3	5
83	Outcomes By Cardiac Stage in Newly Diagnosed AL Amyloidosis: Results from Andromeda. <i>Blood</i> , 2020, 136, 44-45.	0.6	5
84	Imaging Options in Cardiac Amyloidosis: Differentiating AL from ATTR. <i>Current Cardiovascular Imaging Reports</i> , 2017, 10, 1.	0.4	4
85	Familial Amyloid Cardiomyopathy Due to TTR Mutations: An underground Cause of Restrictive Cardiomyopathy. <i>Journal of Cardiac Failure</i> , 2009, 15, 464.	0.7	3
86	Recommendations from the Amyloidosis Research Consortium Educational Roundtable at the American College of Cardiology Annual Meeting, 1 April 2016. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 165-166.	1.4	3
87	Clinical approach to genetic testing in amyloid cardiomyopathy: from mechanism to effective therapies. <i>Current Opinion in Cardiology</i> , 2021, 36, 309-317.	0.8	3
88	Conduction abnormalities and role of cardiac pacing in cardiac amyloidosis: A systematic review. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2021, 44, 2092-2099.	0.5	3
89	Should Histologic Determination of Amyloid Load Determine Management Decisions in Light-Chain Amyloidosis?. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2493-2494.	1.2	2
90	The importance of SPECT cardiac reconstruction for accurate 99mTc-pyrophosphate interpretation in TTR amyloidosis. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 1478-1480.	1.4	2

#	ARTICLE	IF	CITATIONS
91	Abstract 694: More Extensive Left Ventricular Hypertrophy in Transthyretin-Type Cardiac Amyloidosis as Compared to Primary Light-Chain Cardiac Amyloidosis. <i>Circulation</i> , 2008, 118, .	1.6	2
92	Diaphragmatic Motion During Cheyne-Stokes Respiration by Navigator Magnetic Resonance Imaging. <i>Circulation</i> , 2005, 112, e132.	1.6	1
93	Paying at the Pump. <i>Circulation: Cardiovascular Imaging</i> , 2010, 3, 635-637.	1.3	1
94	In Search of the Holy Grail. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 200-202.	2.3	1
95	The Incidence of Atrial Fibrillation Among Patients with AL Amyloidosis Undergoing High Dose Melphalan and Stem Cell Transplantation (HDM/SCT): Experience at a Single Institution. <i>Blood</i> , 2015, 126, 5490-5490.	0.6	1
96	Phenotype Mapping in Cardiac Amyloidosis. <i>Journal of the American College of Cardiology</i> , 2021, 78, 2193-2195.	1.2	1
97	Normal Mechanisms of Hemostasis. , 2006, , 61-69.		0
98	Editor's Note. <i>Circulation: Cardiovascular Imaging</i> , 2017, 10, .	1.3	0
99	Hepatocyte Growth Factor and Cardiac Amyloidosis. <i>JACC: CardioOncology</i> , 2020, 2, 67-69.	1.7	0
100	Abstract 2397: Morbidity and Mortality of Transthyretin (TTR) Amyloid Cardiomyopathy (ATTR-CM): Transthyretin Amyloidosis Cardiac Study (TRACS) a Prospective Evaluation. <i>Circulation</i> , 2008, 118, .	1.6	0
101	High-Dose Melphalan and Stem Cell Transplantation for Patients with AL Amyloidosis and Cardiac Involvement. <i>Blood</i> , 2011, 118, 2043-2043.	0.6	0